Streetbeat News

Products Services

APP

AppLovin has made AI advancements to its user acquisition solution, AppDiscovery, which have resulted in increased efficiency and better performing mobile campaigns.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:44 pm

JAGX

Jaguar Health, Inc. (NASDAQ:JAGX) announced positive results from an independent pilot phase 2 study of crofelemer for the management of neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer. The study showed that crofelemer, Jaguar's FDA approved drug, may be effective for the management of neratinib-induced diarrhea. The results warrant further investigation of crofelemer for treatment of cancer therapy-related diarrhea (CTD). Top line results from the Company's ongoing phase 3 OnTarget clinical trial are expected in late October 2023.

Portfolio Pulse from Happy Mohamed

August 07, 2023 | 12:44 pm

NXL

Nexalin Technology has reported positive results from a clinical study of its Gen-2, 15 milliamp neurostimulation device for treating migraine headaches and related symptoms. The study supports the therapeutic benefits of the device.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:42 pm

AMD

MSFT

NVDA

TSM

Nvidia Corp's stock is trading higher despite the artificial intelligence boom causing a supply chain crisis for GPUs. Microsoft's OpenAI and other companies have taken steps to counter Nvidia's H100 and A100 enterprise GPU crisis. Nvidia has addressed the packaging problem with Taiwan Semiconductor Manufacturing Company's 3D stacking chip-on-wafer-on-substrate technology and promises a more robust supply in the second half of 2023. This situation might present an opportunity for Advanced Micro Devices' Radeon 7900 XTX cards. Nvidia's data center business is expected to double sales in 2023, adding $15 billion. However, Nvidia is considered a proxy for the bubble in AI stocks and is nearing its peak, according to Morgan Stanley strategist Edward Stanley.

Portfolio Pulse from Anusuya Lahiri

August 07, 2023 | 12:41 pm

MNTK

Montauk Renewables has signed a letter of intent with European Energy to provide CO2 for e-Methanol production. The delivery period is set to begin in 2026 and is expected to last for 15 years.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:40 pm

FOXO

AI-driven biotechnology company GERO and epigenetic biomarker discovery leader FOXO Technologies Inc. (NYSEAM:FOXO) have begun discussions to form a strategic collaboration. The partnership aims to develop an AI-driven personalized wellness and longevity recommendation engine based on proprietary epigenetic data.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:38 pm

GRI

GRI Bio has presented preclinical data indicating that oral administration of GRI-0803 inhibited lupus nephritis and significantly improved overall survival in animal models. The company expects to commence Phase 1a/b SLE study in 1H 2024 with topline results expected 2H 2024.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:37 pm

WIMI

WiMi Hologram Cloud Inc. (NASDAQ:WIMI) is developing algorithms for 3D image generation based on Generative Adversarial Networks (GAN). The technology has potential applications in game development, virtual reality, and architectural design, among others. The algorithm generates realistic 3D images through adversarial training of a generator and a discriminator.

Portfolio Pulse from Happy Mohamed

August 07, 2023 | 12:37 pm

GOOG

GOOGL

Google, a subsidiary of Alphabet Inc., has launched a new tool called Pixel Binary Transparency to help users check if their Pixel phones and tablets have been tampered with. The tool is a response to the increasing number of attacks on the software supply chain, which have affected tens of thousands of software users from Fortune 500 companies to branches of the US government.

Portfolio Pulse from Rounak Jain

August 07, 2023 | 12:36 pm

DYAI

Dyadic International, Inc. has announced the results from third-party analytical testing of the company's animal-free recombinant serum albumin. The results are expected to have a significant impact on the company's future operations.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:35 pm